Affinage

MAGI2

Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 · UniProt Q86UL8

Length
1455 aa
Mass
158.8 kDa
Annotated
2026-06-10
100 papers in source corpus 21 papers cited in narrative 21 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MAGI2 is a multi-PDZ/WW domain scaffold protein that organizes membrane-associated signaling complexes at cell-cell junctions, the podocyte slit diaphragm, and neuronal synapses (PMID:10760291, PMID:15994232, PMID:22593065). A core function is stabilization of the tumor suppressor PTEN: the second PDZ domain of MAGI2 engages the PTEN C-terminal PDZ-binding motif, an interaction tuned by PTEN phosphorylation at T382/T383, which enhances PTEN protein stability and suppresses Akt activation (PMID:10760291, PMID:11431330). This stabilization depends on an intact beta-catenin–MAGI2 interface at adherens junctions maintained by vinculin (PMID:15579911), and in hepatocellular carcinoma cells MAGI2 overexpression curbs migration and proliferation and sensitizes cells to apoptosis through PTEN-dependent downregulation of p-FAK and p-Akt (PMID:17880912, PMID:23754155). In podocytes, MAGI2 is a transcriptional target of WT1 and is essential for kidney filter integrity: its loss in mice causes proteinuria, foot process effacement, loss of nephrin, and renal failure (PMID:25271328, PMID:25108225, PMID:25556170). There it scaffolds the slit diaphragm by binding Nephrin and Neph1 through its PDZ domains (PMID:33144214), drives formation of slit diaphragm condensates via liquid-liquid phase separation with Dendrin and CD2AP that recruit Nephrin (PMID:34330769), and activates the small GTPase Rap1 through a complex with RapGEF2 to maintain podocyte actin organization (PMID:31171376); congenital nephrotic syndrome variants disrupt these assemblies (PMID:31171376, PMID:34330769). In neurons, MAGI2 maintains GluA2-containing AMPA receptors at synapses and controls dendritic spine density (PMID:22593065), traffics TARPs/stargazin via PDZ1/3/5 (PMID:16870733), links beta-dystroglycan and neuroligin 2 to organize inhibitory synapses (PMID:17059560), and mediates beta1-adrenergic receptor internalization via PDZ1 (PMID:11526121). MAGI2 also participates in CK2-regulated, SANS-dependent clathrin endocytosis required for photoreceptor ciliogenesis, where USH1G patient mutations abolish MAGI2 binding (PMID:24608321).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 2000 High

    Established MAGI2's founding molecular role by showing it binds and stabilizes PTEN, linking a junctional scaffold to PI3K/Akt suppression.

    Evidence Yeast two-hybrid, co-IP, and Akt suppression assay in epithelial cells

    PMID:10760291

    Open questions at the time
    • Did not define how PTEN recruitment is dynamically regulated
    • Physiological context beyond epithelial tight junctions unaddressed
  2. 2001 High

    Defined the regulatory switch for the MAGI2-PTEN interaction, showing PTEN C-terminal phosphorylation at T382/T383 controls binding affinity and protects PTEN from proteasomal degradation.

    Evidence Site-directed mutagenesis, co-IP, proteasome inhibition, polyubiquitination detection

    PMID:11431330

    Open questions at the time
    • Kinase responsible for T382/T383 phosphorylation not identified
    • In vivo relevance of the phospho-switch untested
  3. 2001 High

    Extended MAGI2 beyond PTEN by mapping a high-affinity beta1AR–PDZ1 interaction that promotes receptor internalization, establishing MAGI2 as a GPCR trafficking scaffold.

    Evidence Overlay assay, pull-down, reciprocal co-IP, internalization assay

    PMID:11526121

    Open questions at the time
    • Endogenous neuronal/cardiac context not examined
    • Mechanism coupling MAGI2 to the internalization machinery unresolved
  4. 2002 Medium

    Revealed MAGI2 as a viral oncoprotein target, with high-risk HPV E6 driving its proteasomal degradation through a single PDZ domain.

    Evidence Co-expression degradation assay with PDZ domain competition

    PMID:12140759

    Open questions at the time
    • Functional consequence of MAGI2 loss for HPV transformation not established
    • Single-lab, two-approach study
  5. 2003 Medium

    Showed MAGI2 controls neurotransmitter receptor trafficking, binding delta2 glutamate receptor in a PKC-phosphorylation-dependent manner.

    Evidence Co-IP and co-expression localization in COS7 cells with PKC phosphorylation assay

    PMID:12589829

    Open questions at the time
    • Limited mechanistic detail beyond localization change
    • Not validated in neurons
  6. 2004 High

    Connected junctional architecture to PTEN stability, demonstrating that vinculin-maintained beta-catenin–MAGI2 interaction at adherens junctions is required to sustain PTEN protein.

    Evidence Vinculin-null cell rescue, E-cadherin blocking antibody, co-IP-linked PTEN stability assay

    PMID:15579911

    Open questions at the time
    • Direct structural basis of the beta-catenin–MAGI2 contact undefined
    • Did not address tissue-specific dependence
  7. 2005 High

    Placed MAGI2 within the podocyte slit diaphragm by identifying it as a component of the nephrin multiprotein complex, opening its renal biology.

    Evidence GST-nephrin pull-down with mass spectrometry and immunofluorescence in glomeruli

    PMID:15994232

    Open questions at the time
    • Functional requirement in podocytes not yet tested
    • Direct vs indirect nephrin association unresolved at this stage
  8. 2006 High

    Defined MAGI2's role at inhibitory synapses, showing it bridges beta-dystroglycan and neuroligin 2 via its WW and PDZ domains into a tripartite complex.

    Evidence Co-IP from rat brain, in vitro reconstitution, domain mapping, neuronal immunofluorescence

    PMID:17059560

    Open questions at the time
    • Functional consequence for inhibitory transmission not measured
    • Stoichiometry of the tripartite complex unknown
  9. 2006 High

    Identified the PDZ determinants for AMPA receptor regulation by mapping MAGI2 binding to the stargazin/TARP -TTPV motif through PDZ1/3/5.

    Evidence Yeast two-hybrid, co-IP from mouse cortex, in vitro binding, cell-based localization

    PMID:16870733

    Open questions at the time
    • Physiological effect on synaptic AMPAR currents not yet shown
    • Selectivity among multiple PDZ domains not fully resolved
  10. 2007 High

    Established MAGI2 as a tumor-suppressive scaffold in cancer cells, with anti-migratory and anti-proliferative effects strictly dependent on PTEN stabilization.

    Evidence MAGI2 transfection, PTEN siRNA and PTEN-null rescue, p-FAK/p-Akt western blot in HCC cells

    PMID:17880912

    Open questions at the time
    • In vivo tumor relevance not addressed
    • Whether MAGI2 is downregulated in primary tumors untested here
  11. 2012 High

    Demonstrated a functional, activity- and PSD-95-independent requirement for MAGI2 in maintaining GluA2-containing AMPA receptors and dendritic spines.

    Evidence Bidirectional RNAi/overexpression with electrophysiology, spine imaging, surface AMPAR measurement in hippocampal neurons

    PMID:22593065

    Open questions at the time
    • Molecular link from MAGI2 to GluA2 surface retention not fully defined
    • In vivo behavioral consequence not examined
  12. 2014 High

    Provided definitive genetic proof that MAGI2 is essential for kidney filter integrity and podocyte survival through constitutive knockout phenotypes, identifying downstream dendrin nuclear translocation and cathepsin L upregulation.

    Evidence Two independent constitutive Magi2 KO mice with histology, EM, proteinuria, and slit diaphragm component analysis

    PMID:25108225 PMID:25271328

    Open questions at the time
    • Cell-autonomous vs systemic contribution not separated by constitutive KO
    • Mechanism triggering dendrin translocation unresolved
  13. 2014 High

    Linked MAGI2 to a ciliopathy pathway, showing CK2-regulated SANS binding directs MAGI2-mediated clathrin endocytosis required for ciliogenesis and photoreceptor function.

    Evidence Y2H, co-IP, RNAi endocytosis assay, retinal immunolocalization, USH1G patient mutation analysis

    PMID:24608321

    Open questions at the time
    • Endocytic cargo regulated by SANS-MAGI2 not defined
    • Direct role of MAGI2 in the endocytic machinery mechanistically incomplete
  14. 2015 Medium

    Placed Magi2 downstream of the master podocyte transcription factor WT1, providing a transcriptional basis for its glomerular expression and a developmental requirement.

    Evidence Glomerular ChIP-seq, WT1 KO microarray, zebrafish morpholino knockdown

    PMID:25556170

    Open questions at the time
    • Direct WT1 binding element not functionally dissected
    • Single-lab transcriptional regulation evidence
  15. 2020 High

    Resolved how MAGI2 anchors the slit diaphragm, showing podocyte-specific loss abrogates Nephrin and Neph1 localization and that its PDZ domains directly engage these backbone proteins.

    Evidence Podocyte-specific KO mouse, co-IP, pull-down, super-resolution microscopy

    PMID:33144214

    Open questions at the time
    • Whether scaffolding is sufficient or requires partner cooperativity untested in this study
  16. 2019 High

    Identified the signaling output of MAGI2 in podocytes, showing it forms a RapGEF2 complex to activate Rap1 and maintain actin organization, with disease variants failing to activate Rap1.

    Evidence Co-IP, Rap1 activity assay, podocyte-specific RapGEF2 KO mouse, CNS variant analysis, pharmacological Rap1 rescue

    PMID:31171376

    Open questions at the time
    • How the MAGI2-RapGEF2 complex is spatially coupled to the slit diaphragm unclear
    • Rap1 effectors driving actin remodeling not delineated
  17. 2021 High

    Defined the biophysical principle of slit diaphragm assembly, showing MAGI2 undergoes liquid-liquid phase separation with Dendrin and CD2AP to form condensates that enrich Nephrin, disrupted by a nephrotic syndrome mutation.

    Evidence In vitro phase separation and complex reconstitution, biophysical assays, cellular condensate imaging, disease mutant analysis

    PMID:34330769

    Open questions at the time
    • In vivo demonstration of condensates in podocytes not established
    • Regulation of condensate dynamics unknown
  18. 2021 High

    Provided atomic-resolution insight into MAGI2 ligand recognition by solving the PDZ4–ARMS PBM crystal structure and revealing a variant binding-groove motif.

    Evidence X-ray crystallography with mutagenesis validation of contact residues

    PMID:34371146

    Open questions at the time
    • Functional role of the MAGI2-ARMS interaction in cells untested
    • Specificity rules across the other PDZ domains not generalized
  19. 2023 Medium

    Placed MAGI2 upstream of TGF-beta signaling in diabetic podocyte injury, with enforced MAGI2 expression protecting podocytes and improving renal function in db/db mice.

    Evidence AAV MAGI2 transduction in db/db mice, high-glucose in vitro model, TGF-beta/apoptotic protein western blots

    PMID:37950637

    Open questions at the time
    • Direct molecular link from MAGI2 to TGF-beta pathway not defined
    • Single-lab in vivo evidence

Open questions

Synthesis pass · forward-looking unresolved questions
  • How MAGI2's distinct multidomain assemblies are selected and coordinated across tissues — junctional PTEN stabilization, podocyte condensate/Rap1 signaling, and synaptic receptor scaffolding — remains unresolved.
  • No integrated structural model of full-length MAGI2 with multiple ligands
  • Regulatory logic governing tissue-specific partner choice unknown
  • Whether PTEN and slit-diaphragm functions intersect in podocytes untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 5 GO:0098772 molecular function regulator activity 4
Localization
GO:0005886 plasma membrane 4 GO:0005634 nucleus 1
Pathway
GO:0005886 plasma membrane 1
Partners
BETA-CATENINCD2APNEPH1NEPHRINNEUROLIGIN 2PTENRAPGEF2STARGAZIN
Complex memberships
MAGI2-RapGEF2 complexbeta-dystroglycan-MAGI2-neuroligin 2 complexnephrin multiprotein complexslit diaphragm (MAGI2-Dendrin-CD2AP condensate)

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2000 MAGI-2 was identified as a binding partner of PTEN via an interaction between the PDZ-binding motif of PTEN and the second PDZ domain of MAGI-2. MAGI-2 localizes to tight junctions in epithelial cell membranes and enhances PTEN's ability to suppress Akt activation, stabilizing PTEN protein. Yeast two-hybrid screen, co-immunoprecipitation, functional Akt suppression assay Proceedings of the National Academy of Sciences of the United States of America High 10760291
2001 PTEN binding to MAGI-2 is regulated by phosphorylation at threonine residues T382 and T383 in PTEN's C-terminus: phosphorylation-incompetent PTEN mutants (T382A/T383A) show dramatically reduced expression due to proteasome-mediated degradation and display significantly greater binding affinity to MAGI-2, suggesting phosphorylation status controls PTEN recruitment to cell-cell junctions via MAGI-2. Site-directed mutagenesis, co-immunoprecipitation, proteasome inhibition assay, polyubiquitination detection Cancer research High 11431330
2001 The beta1-adrenergic receptor (beta1AR) C-terminus binds with high affinity to the first PDZ domain of MAGI-2. Co-expression of MAGI-2 with beta1AR constitutively associates the two proteins (enhanced by agonist), markedly increases agonist-induced beta1AR internalization (opposite to PSD-95 effect), and promotes association of beta1AR with beta-catenin. Overlay assay, pull-down, co-immunoprecipitation, immunofluorescence co-localization The Journal of biological chemistry High 11526121
2002 High-risk HPV E6 proteins target MAGI-2 for proteasome-mediated degradation via a specific interaction with one PDZ domain of MAGI-2; co-expression of that PDZ domain alone can protect full-length MAGI-2 from E6-mediated degradation. Co-expression degradation assay, PDZ domain competition experiment Oncogene Medium 12140759
2003 The delta2 glutamate receptor interacts with MAGI-2 (S-SCAM) at a PDZ domain; PKC-mediated phosphorylation of the receptor regulates this interaction. Co-expression of both proteins in COS7 cells caused drastic changes in delta2 receptor localization, indicating MAGI-2 controls intracellular trafficking of delta2 receptor. Co-immunoprecipitation, co-expression localization in COS7 cells, PKC phosphorylation assay Biochemical and biophysical research communications Medium 12589829
2004 PTEN protein levels depend on the maintenance of the beta-catenin–MAGI-2 interaction at the cell membrane, with vinculin playing a critical role by preserving adherens junction integrity. In vinculin-null cells, MAGI-2 overexpression restored PTEN protein levels, and vinculin mutants that reinstated beta-catenin–MAGI-2 interaction also restored PTEN. Vinculin-null cell transfection, MAGI-2 overexpression rescue, E-cadherin blocking antibody, co-immunoprecipitation-linked PTEN stability assay The Journal of biological chemistry High 15579911
2005 MAGI-2 (S-SCAM) is a component of the nephrin multiprotein complex in podocytes: GST-nephrin cytoplasmic domain pull-down from glomerular lysates specifically retrieved MAGI-2, IQGAP1, CASK, alpha-actinin, alphaII spectrin, and betaII spectrin. MAGI-2 co-localizes with nephrin in podocyte foot processes and appears at junctional complexes after podocyte migration. GST pull-down with mass spectrometry identification, immunofluorescence co-localization Proceedings of the National Academy of Sciences of the United States of America High 15994232
2006 MAGI-2 (S-SCAM) localizes to inhibitory synapses in rat hippocampal neurons where its WW domains bind beta-dystroglycan (beta-DG) and its WW and second PDZ domain bind neuroligin 2. MAGI-2, beta-DG, and neuroligin 2 form a tripartite complex in vitro, and MAGI-2 functions as a linker between the dystrophin glycoprotein complex and the neurexin-neuroligin complex at inhibitory synapses. Co-immunoprecipitation from rat brain, in vitro complex reconstitution, immunofluorescence in primary hippocampal neurons, domain-binding mapping Journal of neurochemistry High 17059560
2006 MAGI-2 interacts with stargazin and other TARPs (transmembrane AMPA receptor regulating proteins) via the C-terminal -TTPV motif of stargazin and the PDZ1, PDZ3, and PDZ5 domains of MAGI-2. Co-immunoprecipitation confirmed the MAGI-2/stargazin interaction in vivo from mouse cerebral cortex. Stargazin expression recruits MAGI-2 to cell membranes and cell-cell contact sites in a -TTPV motif-dependent manner. Yeast two-hybrid screening, co-immunoprecipitation from mouse brain, in vitro binding assay, transfection-based localization in HEK-293T cells The Journal of neuroscience High 16870733
2007 MAGI-2 overexpression in hepatocellular carcinoma cells inhibits migration and proliferation through PTEN upregulation: MAGI-2 increases PTEN protein stability (not mRNA), leading to downregulation of p-FAK and p-Akt. The effect was lost when PTEN was silenced or in PTEN-null cells, and restored by PTEN transfection. Transfection of myc-MAGI-2, PTEN siRNA knockdown, co-immunoprecipitation, western blot for p-FAK and p-Akt, PTEN-null cell rescue Archives of biochemistry and biophysics High 17880912
2012 S-SCAM/MAGI-2 is an essential scaffolding molecule for maintaining GluA2-containing AMPA receptors at synapses. Increasing S-SCAM levels in rat hippocampal neurons increased surface GluA2-containing AMPAR levels, enhanced AMPAR-mediated synaptic transmission, and enlarged dendritic spines without affecting NMDAR EPSCs. Knockdown by RNAi caused loss of synaptic AMPARs and severe reduction of dendritic spine density. S-SCAM regulated AMPARs in a GluA2-dependent manner, independently of activity and PSD-95. RNA interference knockdown, overexpression in rat hippocampal neurons, electrophysiology (AMPAR and NMDAR EPSCs), surface AMPAR measurement The Journal of neuroscience High 22593065
2013 MAGI2 overexpression enhances sensitivity of BEL-7404 hepatocellular carcinoma cells to staurosporine-induced apoptosis by increasing PTEN protein stability and decreasing its degradation, leading to reduced AKT phosphorylation. The pro-apoptotic effect of MAGI-2 was reversed by PTEN siRNA, confirming PTEN dependency. Myc-MAGI2 transfection, Annexin V apoptosis assay, PTEN siRNA knockdown, western blot for PTEN protein levels and p-AKT International journal of molecular medicine Medium 23754155
2014 Magi-2 knockout mice develop progressive proteinuria, podocyte foot process effacement, loss of nephrin expression, podocyte hypertrophy, and die of renal failure by 3 months. MAGI-2 is required for kidney filter integrity and podocyte survival; parietal epithelial cells (PECs) are activated to form glomerular lesions following rapid podocyte loss. Homologous recombination knockout mouse, immunohistochemistry, electron microscopy, proteinuria assay Proceedings of the National Academy of Sciences of the United States of America High 25271328
2014 Homozygous deletion of Magi2 in mice causes neonatal lethality due to podocyte morphological abnormalities and anuria. Loss of MAGI-2 function leads to significant decreases in nephrin and dendrin at the slit diaphragm, nuclear translocation of dendrin, and enhanced expression of cathepsin L, which is critical for actin cytoskeleton rearrangement in podocytes. Constitutive knockout mouse, immunohistological analysis, expression analysis of slit diaphragm components The American journal of pathology High 25108225
2014 MAGI-2 interacts with the USH1G protein SANS through SANS's sterile alpha motif (SAM) domain via an internal PDZ-binding motif, and this interaction is regulated by CK2 phosphorylation of SANS. MAGI-2 participates in clathrin-dependent endocytosis; phosphorylated SANS tightly regulates MAGI-2-mediated endocytosis. SANS-MAGI-2-mediated endocytosis also regulates ciliogenesis. The SANS-MAGI-2 complex localizes to the periciliary membrane complex in retinal photoreceptors. USH1G patient mutations in SANS that eliminate MAGI-2 binding deregulate endocytosis and disrupt photoreceptor cell function. Yeast two-hybrid, co-immunoprecipitation, RNAi knockdown, endocytosis assay, immunolocalization in retina, patient mutation functional analysis Human molecular genetics High 24608321
2015 WT1 (Wilms' tumor suppressor) directly transcriptionally regulates Magi2 expression in podocytes, as identified by chromatin immunoprecipitation sequencing (ChIP-seq) of glomeruli combined with transcriptomic analysis of WT1 knockout mice. Functional assays in zebrafish confirmed Magi2 is required for normal embryonic kidney development. ChIP-seq from glomeruli, cDNA microarray of WT1 knockout mice, zebrafish morpholino knockdown Journal of the American Society of Nephrology Medium 25556170
2019 MAGI2 forms a complex with the Rap1 guanine nucleotide exchange factor RapGEF2, and this complex activates the small GTPase Rap1 in podocytes. MAGI2 congenital nephrotic syndrome (CNS) variants fail to form this complex and do not enhance Rap1 activation. Podocyte-specific RapGEF2 deletion in mice produces spontaneous glomerulosclerosis similar to MAGI2 KO. MAGI2 CNS variant-expressing human podocytes show severe actin cytoskeletal disorganization that is rescued by pharmacological Rap1 activation. Co-immunoprecipitation, Rap1 activation assay, podocyte-specific RapGEF2 conditional KO mouse, RNAi knockdown, pharmacological Rap1 activation rescue, immunostaining of patient kidney sections Kidney international High 31171376
2020 Podocyte-specific deficiency of MAGI-2 in mice abrogates localization of Nephrin and Neph1 at the slit diaphragm independently of other scaffold proteins. The PDZ domains of MAGI-2 are required for its interaction with slit diaphragm backbone proteins Nephrin and Neph1, as shown by co-immunoprecipitation and pull-down assays. Podocyte-specific MAGI-2 knockout mouse, co-immunoprecipitation, pull-down, immunofluorescence, super-resolution microscopy Kidney international High 33144214
2021 MAGI2 can autonomously undergo liquid-liquid phase separation. Multivalent interactions among the MAGI2-Dendrin-CD2AP complex drive formation of highly dense slit diaphragm condensates that recruit Nephrin. A nephrotic syndrome-associated mutation of MAGI2 interferes with condensate formation and impairs Nephrin enrichment. In vitro phase separation assay, biochemical reconstitution of MAGI2-Dendrin-CD2AP complex, biophysical assays, cell biology condensate visualization, disease mutant analysis Journal of the American Society of Nephrology High 34330769
2021 Crystal structure of the MAGI2 PDZ4 domain in complex with the PDZ-binding motif (PBM) of ARMS (ankyrin repeat-rich membrane spanning protein) was solved, revealing a canonical PDZ/PBM interaction at the αB/βB groove. Serial mutagenesis validated key contact residues. The conserved 'GLGF' motif in PSD-95-PDZ3 changes to 'GFGF' in the MAGI2-PDZ4/ARMS-PBM complex. X-ray crystallography, in vitro binding assays, site-directed mutagenesis Neurochemistry international High 34371146
2023 MAGI2 deficiency induced by high-glucose activates TGF-β signaling, which decreases expression of anti-apoptotic proteins in podocytes. AAV-mediated enforced expression of MAGI2 in db/db mice protected podocytes from apoptosis and improved renal function, placing MAGI2 upstream of TGF-β-Smad3/nephrin pathway in podocyte survival. AAV transduction in db/db mice, high-glucose in vitro model, western blot for TGF-β signaling components and apoptotic proteins, renal function measurement FASEB journal Medium 37950637

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2000 Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proceedings of the National Academy of Sciences of the United States of America 340 10760291
2002 Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 166 12140759
2013 MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Molecular cancer therapeutics 158 24258346
2005 Cell junction-associated proteins IQGAP1, MAGI-2, CASK, spectrins, and alpha-actinin are components of the nephrin multiprotein complex. Proceedings of the National Academy of Sciences of the United States of America 136 15994232
2007 Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut 129 17989107
2001 Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer research 127 11431330
2019 LncRNA MAGI2-AS3 Is Regulated by BRD4 and Promotes Gastric Cancer Progression via Maintaining ZEB1 Overexpression by Sponging miR-141/200a. Molecular therapy. Nucleic acids 114 31837602
2001 beta 1-adrenergic receptor association with the synaptic scaffolding protein membrane-associated guanylate kinase inverted-2 (MAGI-2). Differential regulation of receptor internalization by MAGI-2 and PSD-95. The Journal of biological chemistry 106 11526121
2004 Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein beta-catenin with the scaffolding protein MAGI-2. The Journal of biological chemistry 101 15579911
2008 Infantile spasms is associated with deletion of the MAGI2 gene on chromosome 7q11.23-q21.11. American journal of human genetics 97 18565486
2006 Synaptic scaffolding molecule (S-SCAM) membrane-associated guanylate kinase with inverted organization (MAGI)-2 is associated with cell adhesion molecules at inhibitory synapses in rat hippocampal neurons. Journal of neurochemistry 81 17059560
2020 Deregulated lncRNA MAGI2-AS3 in Alzheimer's disease attenuates amyloid-β induced neurotoxicity and neuroinflammation by sponging miR-374b-5p. Experimental gerontology 69 33279663
2018 Long non-coding RNA (lncRNA) MAGI2-AS3 inhibits breast cancer cell growth by targeting the Fas/FasL signalling pathway. Human cell 68 29679339
2019 LncRNA MAGI2-AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR-374b-5p/SMG1 signaling pathway. Journal of cellular physiology 66 30924168
2006 Stargazin and other transmembrane AMPA receptor regulating proteins interact with synaptic scaffolding protein MAGI-2 in brain. The Journal of neuroscience : the official journal of the Society for Neuroscience 65 16870733
2016 MAGI2 Mutations Cause Congenital Nephrotic Syndrome. Journal of the American Society of Nephrology : JASN 60 27932480
2018 Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression. Biochemical and biophysical research communications 58 30442369
2015 Integration of Cistromic and Transcriptomic Analyses Identifies Nphs2, Mafb, and Magi2 as Wilms' Tumor 1 Target Genes in Podocyte Differentiation and Maintenance. Journal of the American Society of Nephrology : JASN 55 25556170
2007 MAGI-2 Inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. Archives of biochemistry and biophysics 53 17880912
2016 MiR-487a Promotes TGF-β1-induced EMT, the Migration and Invasion of Breast Cancer Cells by Directly Targeting MAGI2. International journal of biological sciences 48 27019625
2012 S-SCAM/MAGI-2 is an essential synaptic scaffolding molecule for the GluA2-containing maintenance pool of AMPA receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience 48 22593065
2019 Long non-coding RNA MAGI2-AS3 inhibits breast cancer cell migration and invasion via sponging microRNA-374a. Cancer biomarkers : section A of Disease markers 44 30883342
2020 MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2. Journal of cellular physiology 43 32730644
2019 lncRNA MAGI2-AS3 Prevents the Development of HCC via Recruiting KDM1A and Promoting H3K4me2 Demethylation of the RACGAP1 Promoter. Molecular therapy. Nucleic acids 43 31629962
2019 Long noncoding MAGI2-AS3 promotes colorectal cancer progression through regulating miR-3163/TMEM106B axis. Journal of cellular physiology 42 31709544
2009 MAGI2 genetic variation and inflammatory bowel disease. Inflammatory bowel diseases 40 18720471
2014 MAGI-2 scaffold protein is critical for kidney barrier function. Proceedings of the National Academy of Sciences of the United States of America 37 25271328
2020 LncRNA MAGI2-AS3 inhibits bladder cancer progression by targeting the miR-31-5p/TNS1 axis. Aging 36 33231563
2022 Long noncoding RNA MAGI2-AS3 regulates the H2O2 level and cell senescence via HSPA8. Redox biology 34 35797800
2020 LncRNA MAGI2-AS3 Overexpression Sensitizes Esophageal Cancer Cells to Irradiation Through Down-Regulation of HOXB7 via EZH2. Frontiers in cell and developmental biology 33 33330444
2019 Long Non-Coding RNA MAGI2-AS3 is a New Player with a Tumor Suppressive Role in High Grade Serous Ovarian Carcinoma. Cancers 33 31842477
2014 MAGI-2 is critical for the formation and maintenance of the glomerular filtration barrier in mouse kidney. The American journal of pathology 33 25108225
2023 MAGI2-AS3 and miR-374b-5p as Putative Regulators of Multiple Sclerosis via Modulating the PTEN/AKT/IRF-3/IFN-β Axis: New Clinical Insights. ACS chemical neuroscience 31 36878000
2021 Roles of lncRNA MAGI2-AS3 in human cancers. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 31 34126355
2012 Common variants in MAGI2 gene are associated with increased risk for cognitive impairment in schizophrenic patients. PloS one 31 22649501
2020 LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia. RNA biology 29 32174258
2003 PKC regulates the delta2 glutamate receptor interaction with S-SCAM/MAGI-2 protein. Biochemical and biophysical research communications 29 12589829
2019 LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis. European review for medical and pharmacological sciences 28 31539127
2020 Long noncoding RNA MAGI2-AS3/miR-218-5p/GDPD5/SEC61A1 axis drives cellular proliferation and migration and confers cisplatin resistance in nasopharyngeal carcinoma. International forum of allergy & rhinology 27 32450008
2015 MAGI2/S-SCAM outside brain. Journal of biochemistry 27 25637633
2020 MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis. Cancer medicine 26 32681706
2020 Long Noncoding MAGI2-AS3 Suppresses Several Cellular Processes of Lung Squamous Cell Carcinoma Cells by Regulating miR-374a/b-5p/CADM2 Axis. Cancer management and research 25 32021443
2014 Phosphorylation of the Usher syndrome 1G protein SANS controls Magi2-mediated endocytosis. Human molecular genetics 23 24608321
2010 Deletion of 7q11.21-q11.23 and infantile spasms without deletion of MAGI2. American journal of medical genetics. Part A 23 20101691
2021 LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor HEY1 in clear cell renal cell carcinoma. Cancer gene therapy 22 34002044
2020 LncRNA MAGI2-AS3 is down-regulated in intervertebral disc degeneration and participates in the regulation of FasL expression in nucleus pulposus cells. BMC musculoskeletal disorders 22 32143617
2019 Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2. Kidney international 22 31171376
2019 LncRNA MAGI2-AS3 is involved in cervical squamous cell carcinoma development through CDK6 up-regulation. Infectious agents and cancer 22 31832086
2021 Novel insights for lncRNA MAGI2-AS3 in solid tumors. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 21 33761624
2020 LncRNA MAGI2-AS3 Upregulates Cytokine Signaling 1 by Sponging miR-155 in Non-Small Cell Lung Cancer. Cancer biotherapy & radiopharmaceuticals 21 31910343
2020 LncRNA MAGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25. BMC pulmonary medicine 20 32138716
2020 MAGI-2 orchestrates the localization of backbone proteins in the slit diaphragm of podocytes. Kidney international 20 33144214
2013 MAGI2 enhances the sensitivity of BEL-7404 human hepatocellular carcinoma cells to staurosporine-induced apoptosis by increasing PTEN stability. International journal of molecular medicine 18 23754155
2021 Expression and clinical significance of SYNE1 and MAGI2 gene promoter methylation in gastric cancer. Medicine 17 33530176
2021 Long noncoding RNA MAGI2-AS3 inhibits bladder cancer progression through MAGI2/PTEN/epithelial-mesenchymal transition (EMT) axis. Cancer biomarkers : section A of Disease markers 16 33104021
2020 LncRNA MAGI2-AS3 Affects Cell Invasion and Migration of Cervical Squamous Cell Carcinoma (CSCC) via Sponging miRNA-233/EPB41L3 Axis. Cancer management and research 16 32581592
2016 MAGI-2 in prostate cancer: an immunohistochemical study. Human pathology 16 26980016
2024 LncRNA MAGI2-AS3 promotes fracture healing through downregulation of miR-223-3p. Journal of orthopaedic surgery and research 15 38907263
2023 lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axis. Genomics 15 36889366
2022 Identification and Verification of a Novel MAGI2-AS3/miRNA-374-5p/FOXO1 Network Associated with HBV-Related HCC. Cells 15 36359865
2012 Generation of Venus reporter knock-in mice revealed MAGI-2 expression patterns in adult mice. Gene expression patterns : GEP 15 22361463
2019 MAGI2 Gene Region and Celiac Disease. Frontiers in nutrition 14 31921880
2022 LncRNA MAGI2-AS3 Inhibits Prostate Cancer Progression by Targeting the miR-142-3p. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 13 35944561
2022 Exosomal long noncoding RNAs MAGI2-AS3 and CCDC144NL-AS1 in oral squamous cell carcinoma development via the PI3K-AKT-mTOR signaling pathway. Pathology, research and practice 13 36401978
2021 LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression by targeting the miR-629-5p/TXNIP axis. Annals of translational medicine 13 35071487
2020 MAGI2-AS3 rs7783388 polymorphism contributes to colorectal cancer risk through altering the binding affinity of the transcription factor GR to the MAGI2-AS3 promoter. Journal of clinical laboratory analysis 13 32533587
2020 LncRNA MAGI2-AS3 is downregulated in the distant recurrence of hepatocellular carcinoma after surgical resection and affects migration and invasion via ROCK2. Annals of hepatology 13 32546442
2018 MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. The Prostate 13 29542165
2018 MAGI-2 and scaffold proteins in glomerulopathy. American journal of physiology. Renal physiology 13 30110567
2022 Long non-coding RNA MAGI2-AS3 inactivates STAT3 pathway to inhibit prostate cancer cell proliferation via acting as a microRNA-424-5p sponge. Journal of Cancer 12 34976194
2023 LncRNA MAGI2-AS3-Encoded Polypeptide Restrains the Proliferation and Migration of Breast Cancer Cells. Molecular biotechnology 11 37358745
2022 MicroRNA MiR-490-5p suppresses pancreatic cancer through regulating epithelial-mesenchymal transition via targeting MAGI2 antisense RNA 3. Bioengineered 11 35043728
2021 Phase Separation of MAGI2-Mediated Complex Underlies Formation of Slit Diaphragm Complex in Glomerular Filtration Barrier. Journal of the American Society of Nephrology : JASN 10 34330769
2023 GWAS of depression in 4,520 individuals from the Russian population highlights the role of MAGI2 (S-SCAM) in the gut-brain axis. Frontiers in genetics 9 36685848
2023 MAGI2 ameliorates podocyte apoptosis of diabetic kidney disease through communication with TGF-β-Smad3/nephrin pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 9 37950637
2021 Polymorphism in the MAGI2 Gene Modifies the Effect of Amyloid β on Neurodegeneration. Alzheimer disease and associated disorders 8 33323781
2021 lncRNA MAGI2-AS3 Exerts Antioncogenic Roles in Hepatocellular Carcinoma via Regulating the miR-519c-3p/TXNIP Axis. Journal of oncology 8 34484334
2016 MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma:  A Comparison With AMACR. American journal of clinical pathology 8 27543977
2023 Hypermethylation-Mediated lncRNA MAGI2-AS3 Downregulation Facilitates Malignant Progression of Laryngeal Squamous Cell Carcinoma via Interacting With SPT6. Cell transplantation 7 36852700
2021 lncRNA MAGI2-AS3 overexpression had antitumor effect on Hepatic cancer via miRNA-23a-3p/PTEN axis. Food science & nutrition 7 34026068
2020 MAGI-2 downregulation: a potential predictor of tumor progression and early recurrence in Han Chinese patients with prostate cancer. Asian journal of andrology 7 32167077
2024 Long non-coding RNAs PTENP1, GNG12-AS1, MAGI2-AS3 and MEG3 as tumor suppressors in breast cancer and their associations with clinicopathological parameters. Cancer biomarkers : section A of Disease markers 6 38277283
2023 Role of lncRNA MAGI2-AS3 in lipopolysaccharide-induced nucleus pulposus cells injury by regulating miR-374b-5p/interleukin-10 axis. Immunity, inflammation and disease 6 37102649
2023 Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells. Drug development research 5 37551766
2022 LncRNA MAGI2-As3 Suppresses the Proliferation and Invasion of Cervical Cancer by Sponging MiR-15b. Journal of healthcare engineering 5 35126958
2021 GLIDR promotes the progression of glioma by regulating the miR-4677-3p/MAGI2 axis. Experimental cell research 5 34237299
2024 BMSC derived EVs inhibit colorectal Cancer progression by transporting MAGI2-AS3 or something similar. Cellular signalling 4 38806109
2022 The TLR4/NF-κB/MAGI-2 signaling pathway mediates postoperative delirium. Aging 4 35294925
2021 Comparative study of immunohistochemical expression of ERG and MAGI2 in prostatic carcinoma. Annals of diagnostic pathology 4 33713943
2023 LncRNA MAGI2-AS3 inhibites tumor progression by up-regulating STAM via interacting with miR-142-3p in clear cell renal cell carcinoma. Cellular signalling 3 38084836
2022 MAGI2-AS3 restrains proliferation, glycolysis, and triggers apoptosis in acute lymphoblastic leukemia via regulating miR-452-5p/FOXN3 pathway. Iranian journal of basic medical sciences 3 35656441
2021 Crystal structure of the PDZ4 domain of MAGI2 in complex with PBM of ARMS reveals a canonical PDZ recognition mode. Neurochemistry international 3 34371146
2025 LncRNA MAGI2-AS3 promotes the progression of atherosclerosis by sponging miR-525-5p. Journal of cardiothoracic surgery 2 40247354
2025 The differential expression of MAGI2 in glomerulopathies and its application as a molecular discriminator of podocytopathies. Journal of translational medicine 2 40563084
2024 [LncRNA MAGI2-AS3 enhances cisplatin sensitivity of non-small cell lung cancer cells by regulating the miR-1269a/PTEN/AKT pathway]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2 39523104
2023 Role of MAGI2-AS3 in malignant and non-malignant disorders. Pathology, research and practice 2 37196468
2021 Genetic variants of SDCCAG8 and MAGI2 in mitosis-related pathway genes are independent predictors of cutaneous melanoma-specific survival. Cancer science 2 34375487
2018 The MAGI2 gene polymorphism rs2160322 is associated with Graves' disease but not with Hashimoto's thyroiditis. Journal of endocrinological investigation 2 30535759
2014 Seizure Disorder in a Patient with a 5.09 Mb 7q11.23-q21.11 Microdeletion Including the MAGI2 Gene. Journal of the Association of Genetic Technologists 2 26030165
2023 Long Noncoding RNA MAGI2-AS3 Represses Cell Progression in Clear Cell Renal Cell Carcinoma by Modulating the miR-629-5p/PRDM16 Axis. Critical reviews in eukaryotic gene expression 1 37602452

Missed literature

Know a paper Affinage missed for MAGI2? Flag it for the maintainers and the community.

No submissions yet.